Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

140.59
-0.4600-0.33%
Volume:1.17M
Turnover:165.30M
Market Cap:268.25B
PE:21.25
High:141.57
Open:141.45
Low:140.12
Close:141.05
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:1.86
T/O Rate:0.06%
Dividend:4.67
Dividend Rate:3.32%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.46
PE(LYR):19.66

Loading ...

Alteogen enters option, license agreement with Novartis

TIPRANKS
·
Sep 02

Novartis Trial Suspensions to Have Limited Financial Impact

Dow Jones
·
Sep 02

H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi

TIPRANKS
·
Sep 01

Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity

Dow Jones
·
Sep 01

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

TIPRANKS
·
Sep 01

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

TradingKey
·
Sep 01

Novartis's Multiple Sclerosis Trial Results Match Best Hopes

Dow Jones
·
Sep 01

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Stock News
·
Sep 01

Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023

Dow Jones
·
Sep 01

Movement Alert|Novartis AG Rises 6.73% in Regular Trading, MS Oral Drug Remibrutinib Meets Primary Endpoints in Phase 3 Trials

Market Focus
·
Sep 01

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Sep 01

【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92

TradingKey
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Dow Jones
·
Sep 01

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Dow Jones
·
Sep 01

Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib

TIPRANKS
·
Sep 01

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

TIPRANKS
·
Sep 01

Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT Newswires Live
·
Sep 01

Movement Alert|Novartis AG Rises 5.22% in Pre-Market Trading, CAR-T Autoimmune Trial Halt Paired with Positive MS Oral Drug Data

Market Focus
·
Sep 01

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

Stock News
·
Sep 01